Quest Diagnostics (DGX) Stock Forecast, Price Target & Predictions
DGX Stock Forecast
Quest Diagnostics stock forecast is as follows: an average price target of $154.91 (represents a 0.34% upside from DGX’s last price of $154.38) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
DGX Price Target
The average price target for Quest Diagnostics (DGX) is $154.91 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $190.00 to $125.00. This represents a potential 0.34% upside from DGX's last price of $154.38.
DGX Analyst Ratings
According to 11 Wall Street analysts, Quest Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for DGX stock is 1 'Strong Buy' (9.09%), 5 'Buy' (45.45%), 4 'Hold' (36.36%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Quest Diagnostics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | Ann Hynes | Mizuho Securities | $160.00 | $143.21 | 11.72% | 3.64% |
| Jul 24, 2024 | Eric Coldwell | Robert W. Baird | $154.00 | $140.96 | 9.25% | -0.25% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $158.00 | $144.11 | 9.64% | 2.34% |
| Apr 25, 2024 | Stephanie Davis | Barclays | $144.00 | $137.55 | 4.69% | -6.72% |
| Feb 07, 2024 | Brian Tanquilut | Jefferies | $155.00 | $127.42 | 21.64% | 0.40% |
| Feb 03, 2023 | - | Wells Fargo | $140.00 | $143.29 | -2.30% | -9.31% |
| Jan 06, 2023 | - | Morgan Stanley | $158.00 | $155.50 | 1.61% | 2.34% |
| Nov 17, 2022 | - | Citigroup | $125.00 | $149.27 | -16.26% | -19.03% |
| May 03, 2022 | - | Morgan Stanley | $142.00 | $136.13 | 4.31% | -8.02% |
| Apr 25, 2022 | - | Wells Fargo | $150.00 | $133.75 | 12.15% | -2.84% |
The latest Quest Diagnostics stock forecast, released on Jul 29, 2024 by Ann Hynes from Mizuho Securities, set a price target of $160.00, which represents a 11.72% increase from the stock price at the time of the forecast ($143.21), and a 3.64% increase from DGX last price ($154.38).
Quest Diagnostics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 5 |
| Avg Price Target | - | $157.33 | $154.20 |
| Last Closing Price | $154.38 | $154.38 | $154.38 |
| Upside/Downside | -100.00% | 1.91% | -0.12% |
In the current month, the average price target of Quest Diagnostics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Quest Diagnostics's last price of $154.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 29, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Jul 15, 2024 | Zacks Investment Research | Buy | Buy | Hold |
| Jul 10, 2024 | Citigroup | Neutral | Buy | Upgrade |
| Jun 13, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 30, 2024 | UBS | Buy | Buy | Hold |
| May 30, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Apr 25, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Mar 20, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Mar 20, 2024 | Truist Financial | Market Perform | Market Perform | Hold |
Quest Diagnostics's last stock rating was published by Barclays on Aug 27, 2024. The company gave DGX a "Equal-Weight" rating, the same as its previous rate.
Quest Diagnostics Financial Forecast
Quest Diagnostics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $2.29B | - | $2.34B | $2.33B | $2.33B | $2.49B | - | $2.61B | $2.74B | $2.77B | $2.55B | $2.72B | $3.00B | $2.79B | $1.83B | $1.82B | $1.93B | $1.96B |
| Avg Forecast | $2.59B | $2.60B | $2.63B | $2.60B | $2.53B | $2.53B | $2.55B | $2.51B | $2.46B | $2.41B | $2.39B | $2.29B | $2.25B | $2.27B | $2.26B | $2.20B | $2.26B | $2.35B | $2.34B | $2.64B | $2.68B | $2.45B | $2.39B | $2.64B | $2.93B | $2.72B | $1.69B | $1.75B | $1.92B | $1.94B |
| High Forecast | $2.69B | $2.70B | $2.73B | $2.70B | $2.63B | $2.63B | $2.65B | $2.61B | $2.55B | $2.51B | $2.48B | $2.38B | $2.26B | $2.33B | $2.35B | $2.28B | $2.34B | $2.44B | $2.34B | $2.67B | $2.71B | $2.48B | $2.42B | $2.67B | $2.96B | $2.75B | $1.71B | $1.77B | $1.94B | $1.97B |
| Low Forecast | $2.55B | $2.56B | $2.59B | $2.56B | $2.49B | $2.49B | $2.51B | $2.47B | $2.42B | $2.38B | $2.35B | $2.25B | $2.23B | $2.24B | $2.22B | $2.16B | $2.22B | $2.31B | $2.34B | $2.60B | $2.64B | $2.42B | $2.35B | $2.60B | $2.89B | $2.68B | $1.66B | $1.73B | $1.89B | $1.92B |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | - | 1.04% | 1.06% | 1.03% | 1.06% | - | 0.99% | 1.03% | 1.13% | 1.07% | 1.03% | 1.03% | 1.02% | 1.08% | 1.04% | 1.00% | 1.01% |
Quest Diagnostics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.29B, with a low forecast of $2.25B, and a high forecast of $2.38B. DGX's average Quarter revenue forecast represents a -0.05% decrease compared to the company's last Quarter revenue of $2.29B (Dec 23).
Quest Diagnostics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $267.00M | - | $466.00M | $419.00M | $257.00M | $492.00M | - | $595.00M | $647.00M | $797.00M | $946.00M | $761.00M | $908.00M | $876.00M | $382.00M | $251.00M | $451.00M | $404.00M |
| Avg Forecast | $585.27M | $587.81M | $594.06M | $587.05M | $570.60M | $570.98M | $576.14M | $566.79M | $554.79M | $544.08M | $539.67M | $676.43M | $508.85M | $512.33M | $509.79M | $614.94M | $509.61M | $547.94M | $528.67M | $559.03M | $616.48M | $498.13M | $843.82M | $750.74M | $856.60M | $739.79M | $379.29M | $236.90M | $431.27M | $392.19M |
| High Forecast | $608.01M | $610.65M | $617.15M | $609.86M | $592.78M | $593.17M | $598.53M | $588.82M | $576.34M | $566.75M | $560.64M | $811.72M | $511.11M | $525.13M | $529.60M | $737.92M | $529.42M | $657.52M | $528.67M | $670.84M | $739.78M | $597.75M | $1.01B | $900.89M | $1.03B | $887.74M | $455.15M | $284.28M | $517.52M | $470.62M |
| Low Forecast | $575.66M | $578.16M | $584.31M | $577.42M | $561.24M | $561.61M | $566.68M | $557.49M | $545.68M | $537.28M | $530.81M | $541.14M | $504.32M | $505.48M | $501.43M | $491.95M | $501.25M | $438.35M | $528.67M | $447.23M | $493.18M | $398.50M | $675.06M | $600.60M | $685.28M | $591.83M | $303.43M | $189.52M | $345.01M | $313.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.52% | - | 0.91% | 0.68% | 0.50% | 0.90% | - | 1.06% | 1.05% | 1.60% | 1.12% | 1.01% | 1.06% | 1.18% | 1.01% | 1.06% | 1.05% | 1.03% |
4 analysts predict DGX's average Quarter EBITDA for Mar 24 to be $676.43M, with a high of $811.72M and a low of $541.14M. This is 153.34% upper than Quest Diagnostics's previous annual EBITDA (Dec 23) of $267.00M.
Quest Diagnostics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $192.00M | - | $235.00M | $202.00M | $101.00M | $256.00M | - | $355.00M | $388.00M | $505.00M | $631.00M | $469.00M | $579.00M | $568.00M | $185.00M | $99.00M | $253.00M | $215.00M |
| Avg Forecast | $287.63M | $304.30M | $309.91M | $266.75M | $266.64M | $278.60M | $286.31M | $247.56M | $249.44M | $255.46M | $261.50M | $394.96M | $236.73M | $245.09M | $253.88M | $359.05M | $214.03M | $347.19M | $256.63M | $326.41M | $371.60M | $315.63M | $562.84M | $462.68M | $546.23M | $479.68M | $183.69M | $93.44M | $241.93M | $208.71M |
| High Forecast | $302.16M | $319.67M | $325.56M | $280.23M | $280.10M | $292.67M | $300.77M | $260.06M | $262.04M | $261.09M | $274.71M | $473.95M | $241.15M | $251.80M | $266.71M | $430.86M | $224.84M | $416.63M | $256.63M | $391.69M | $445.92M | $378.75M | $675.41M | $555.22M | $655.47M | $575.61M | $220.43M | $112.13M | $290.32M | $250.46M |
| Low Forecast | $281.50M | $297.81M | $303.29M | $261.06M | $260.95M | $272.65M | $280.20M | $242.28M | $244.12M | $250.96M | $255.92M | $315.96M | $233.41M | $233.90M | $248.47M | $287.24M | $209.46M | $277.75M | $256.63M | $261.13M | $297.28M | $252.50M | $450.27M | $370.14M | $436.98M | $383.74M | $146.95M | $74.75M | $193.54M | $166.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | - | 0.93% | 0.56% | 0.47% | 0.74% | - | 1.09% | 1.04% | 1.60% | 1.12% | 1.01% | 1.06% | 1.18% | 1.01% | 1.06% | 1.05% | 1.03% |
Quest Diagnostics's average Quarter net income forecast for Mar 24 is $394.96M, with a range of $315.96M to $473.95M. DGX's average Quarter net income forecast represents a 105.71% increase compared to the company's last Quarter net income of $192.00M (Dec 23).
Quest Diagnostics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $407.00M | - | $416.00M | $439.00M | $563.00M | $464.00M | - | $425.00M | $464.00M | $427.00M | $429.00M | $407.00M | $447.00M | $396.00M | $360.00M | $377.00M | $299.00M | $379.00M |
| Avg Forecast | $454.40M | $456.37M | $461.22M | $455.78M | $443.01M | $443.30M | $447.30M | $440.05M | $430.73M | $422.42M | $418.99M | $472.83M | $395.06M | $397.76M | $395.80M | $429.85M | $395.66M | $293.56M | $410.45M | $390.77M | $442.11M | $266.88M | $382.66M | $401.51M | $421.70M | $334.42M | $357.45M | $355.82M | $285.92M | $367.92M |
| High Forecast | $472.05M | $474.10M | $479.14M | $473.49M | $460.22M | $460.53M | $464.69M | $457.15M | $447.46M | $440.02M | $435.27M | $567.40M | $396.82M | $407.70M | $411.18M | $515.82M | $411.03M | $352.27M | $410.45M | $468.93M | $530.54M | $320.25M | $459.19M | $481.82M | $506.04M | $401.31M | $428.94M | $426.98M | $343.10M | $441.50M |
| Low Forecast | $446.94M | $448.87M | $453.65M | $448.30M | $435.74M | $436.02M | $439.96M | $432.83M | $423.66M | $417.14M | $412.11M | $378.27M | $391.55M | $392.45M | $389.30M | $343.88M | $389.16M | $234.85M | $410.45M | $312.62M | $353.69M | $213.50M | $306.13M | $321.21M | $337.36M | $267.54M | $285.96M | $284.66M | $228.74M | $294.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | - | 1.05% | 1.02% | 1.42% | 1.58% | - | 1.09% | 1.05% | 1.60% | 1.12% | 1.01% | 1.06% | 1.18% | 1.01% | 1.06% | 1.05% | 1.03% |
Quest Diagnostics's average Quarter SG&A projection for Mar 24 is $472.83M, based on 4 Wall Street analysts, with a range of $378.27M to $567.40M. The forecast indicates a 16.18% rise compared to DGX last annual SG&A of $407.00M (Dec 23).
Quest Diagnostics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.71 | - | $2.08 | $1.80 | $0.89 | $2.20 | - | $2.97 | $3.18 | $4.11 | $5.05 | $3.52 | $4.28 | $4.20 | $1.38 | $0.74 | $1.88 | $1.59 |
| Avg Forecast | $2.57 | $2.72 | $2.77 | $2.38 | $2.38 | $2.49 | $2.56 | $2.21 | $2.23 | $2.28 | $2.33 | $1.86 | $2.11 | $2.19 | $2.27 | $1.97 | $1.91 | $2.19 | $2.29 | $2.99 | $3.22 | $2.88 | $2.87 | $3.71 | $4.17 | $3.72 | $0.71 | $0.88 | $1.60 | $1.71 |
| High Forecast | $2.70 | $2.85 | $2.91 | $2.50 | $2.50 | $2.61 | $2.69 | $2.32 | $2.34 | $2.33 | $2.45 | $1.95 | $2.15 | $2.25 | $2.38 | $2.07 | $2.01 | $2.30 | $2.29 | $3.04 | $3.27 | $2.92 | $2.92 | $3.77 | $4.24 | $3.78 | $0.72 | $0.89 | $1.63 | $1.74 |
| Low Forecast | $2.51 | $2.66 | $2.71 | $2.33 | $2.33 | $2.43 | $2.50 | $2.16 | $2.18 | $2.24 | $2.28 | $1.82 | $2.08 | $2.09 | $2.22 | $1.93 | $1.87 | $2.15 | $2.29 | $2.94 | $3.16 | $2.82 | $2.82 | $3.64 | $4.09 | $3.65 | $0.70 | $0.86 | $1.57 | $1.68 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | - | 0.92% | 0.91% | 0.47% | 1.00% | - | 0.99% | 0.99% | 1.43% | 1.76% | 0.95% | 1.03% | 1.13% | 1.94% | 0.84% | 1.17% | 0.93% |
According to 4 Wall Street analysts, Quest Diagnostics's projected average Quarter EPS for Mar 24 is $1.86, with a low estimate of $1.82 and a high estimate of $1.95. This represents a 8.52% increase compared to DGX previous annual EPS of $1.71 (Dec 23).
Quest Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CRL | Charles River Laboratories | $198.61 | $324.46 | 63.37% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| A | Agilent | $137.31 | $144.90 | 5.53% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| RVTY | Revvity | $122.03 | $123.83 | 1.48% | Hold |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| DGX | Quest Diagnostics | $154.38 | $154.91 | 0.34% | Buy |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.35% | Hold |
| IDXX | IDEXX Laboratories | $500.55 | $479.75 | -4.16% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
DGX Forecast FAQ
Is Quest Diagnostics a good buy?
Yes, according to 11 Wall Street analysts, Quest Diagnostics (DGX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 54.55% of DGX's total ratings.
What is DGX's price target?
Quest Diagnostics (DGX) average price target is $154.91 with a range of $125 to $190, implying a 0.34% from its last price of $154.38. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Quest Diagnostics stock go up soon?
According to Wall Street analysts' prediction for DGX stock, the company can go up by 0.34% (from the last price of $154.38 to the average price target of $154.91), up by 23.07% based on the highest stock price target, and down by -19.03% based on the lowest stock price target.
Can Quest Diagnostics stock reach $200?
DGX's average twelve months analyst stock price target of $154.91 does not support the claim that Quest Diagnostics can reach $200 in the near future.
What are Quest Diagnostics's analysts' financial forecasts?
Quest Diagnostics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $10.12B (high $10.51B, low $9.95B), average EBITDA is $2.28B (high $2.37B, low $2.25B), average net income is $1.08B (high $1.13B, low $1.06B), average SG&A $1.77B (high $1.84B, low $1.74B), and average EPS is $9.63 (high $10.12, low $9.43). DGX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $10.43B (high $10.83B, low $10.25B), average EBITDA is $2.35B (high $2.45B, low $2.32B), average net income is $1.17B (high $1.23B, low $1.14B), average SG&A $1.83B (high $1.9B, low $1.8B), and average EPS is $10.43 (high $10.96, low $10.21).
Did the DGX's actual financial results beat the analysts' financial forecasts?
Based on Quest Diagnostics's last annual report (Dec 2023), the company's revenue was $9.25B, beating the average analysts forecast of $8.98B by 3.06%. Apple's EBITDA was $1.26B, missing the average prediction of $2.15B by -41.19%. The company's net income was $854M, missing the average estimation of $1.09B by -21.99%. Apple's SG&A was $1.64B, beating the average forecast of $1.62B by 1.45%. Lastly, the company's EPS was $7.63, missing the average prediction of $8.54 by -10.69%. In terms of the last quarterly report (Dec 2023), Quest Diagnostics's revenue was $2.29B, beating the average analysts' forecast of $2.25B by 1.53%. The company's EBITDA was $267M, missing the average prediction of $508.85M by -47.53%. Quest Diagnostics's net income was $192M, missing the average estimation of $236.73M by -18.89%. The company's SG&A was $407M, beating the average forecast of $395.06M by 3.02%. Lastly, the company's EPS was $1.71, missing the average prediction of $2.11 by -19.10%